Project Grant R01HL172492

Award Date 6/15/24
Completion Date 5/31/28
Dollars Obligated $2M
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Maywood, IL 60153, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $2,408,580 to evaluate the AMPK-BACH1-NRF2 signaling pathway as a potential therapeutic target for inherited dilated cardiomyopathy (DCM). The primary objective is to investigate whether activating this pathway can restore contractile function in human induced pluripotent stem cell cardiomyocytes with DCM-causing mutations, and whether it can mitigate clinical...
This Project Grant award of $730,764 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Case Western Reserve University (CWRU) supports research to define the effects of cardiac myosin binding protein C (cMyBP-C) genetic variants on cardiac sarcomere structure and function, and link these mechanisms to the development of hypertrophic cardiomyopathy. The 4-year project aims to utilize advanced techniques like cryo-electron microscopy,...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $618,045 project grant (R01HL172871) to the University of Arizona to conduct research on identifying new mechanisms and targets for early onset diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The research, spanning from December 2024 to November 2028, aims to fully characterize three functional domains of the cardiac thin filament linked to the regulation...
This Project Grant award of $194,375, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to determine how extracellular matrix remodeling during cardiomyopathy alters myocardial viscoelasticity and the extent to which those mechanical changes can drive disease progression. The award, with a period of performance from December 2024 to November 2026, will be executed by the University of California, Santa Barbara. The research will...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $2,044,805 to Case Western Reserve University to conduct a collaborative research project aimed at advancing the understanding of molecular mechanisms by which inherited mutations in cardiac myosin binding protein C (cMyBP-C) cause hypertrophic cardiomyopathy. The 4-year project integrates experimental approaches spanning molecular biology, biophysics, physiology,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $100,480 to The University of Texas Southwestern Medical Center to conduct research on understanding the roles of nuclear envelope proteins and DNA damage in cardiomyopathy. The key objectives of this 2-year research project are to: 1) characterize the DNA damage and DNA damage response in cardiomyocytes carrying LEMD2 mutations...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $711,039 to the Research Institute at Nationwide Children's Hospital to investigate the role of cardiac m6A methyltransferases in the pathogenesis of fetal dilated cardiomyopathy (DCM). The key objectives are to determine the functions of the methyltransferases METTL3 and METTL14 in embryonic mouse myocardium, and identify the molecular mechanisms by which they...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) will support research on the mechanistic role of the FHOD3 genetic variant in cardiac autophagy and its impact on the development of hypertrophic cardiomyopathy (HCM) and heart failure. The total award amount is $2,185,454.00 over the project period from August 22, 2024 to May 31, 2028. The...
This $767,579 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to leverage large-scale biobanks to discover and define rare variant effects in hypertrophic cardiomyopathy (HCM). The key objectives are to: Define the contribution and phenotypic manifestations of established HCM disease genes in diverse, non-referral populations. Assess the pathogenicity of candidate HCM genes and establish a platform to evaluate variants of...
The University of Connecticut Health Center received a $615,006 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research (CFDA 93.837) program. The award, effective December 15, 2024 through November 30, 2028, will fund research to reclassify and determine the pathogenicity and pathophysiology of variants of unknown significance in the TNNT2 gene, which encodes an essential component of the cardiac sarcomere. Key research activities...

STRUCTURAL AND FUNCTIONAL BASIS OF MYOCARDIAL DYSREGULATION IN GENETIC CARDIOMYOPATHY - OVER THE PAST SEVERAL DECADES, AND ACCELERATING IN RECENT YEARS, THE SARCOMERE HAS BEEN APPRECIATED AS BOTH THE HOTSPOT FOR CARDIOMYOPATHY-CAUSING VARIANTS AND AS A PROMISING DRUG TARGET. THESE VARIANTS CAN ALTER THE STRUCTURE AND REGULATION OF THE SARCOMERE, LEADING TO ALTERED FUNCTION. THE FIELD HAS MADE SIGNIFICANT PROGRESS IN UNDERSTANDING THESE EFFECTS USING VARIOUS MODELS AND WHILE EACH OF THESE HAVE STRENGTHS, THEY ALL HAVE CAVEATS THAT LIMIT THEIR UTILITY IN UNDERSTANDING THE IN VIVO IMPACT OF CARDIOMYOPATHY-INDUCING VARIANTS. THE PORCINE HEART, THE MOST ACCURATE ANIMAL MODEL OF HUMAN HEARTS, HAS SIMILAR ISOFORM COMPOSITION, STRUCTURE, HEART RATE, AND RESPONSE TO PHYSIOLOGICAL STIMULI, ALLOWING STUDIES ON LIVE MUSCLE THAT ARE NOT FEASIBLE WITH BIOBANKED HUMAN SAMPLES. OUR RESEARCH TEAM IS UNIQUELY SUITED FOR THE SOPHISTICATED EXPERIMENTS NECESSARY TO PERFORM THESE STUDIES. TO INTERROGATE THE STRUCTURAL IMPACT OF THESE VARIANTS, WE WILL USE SYNCHROTRON X-RAY DIFFRACTION, THE ONLY TECHNIQUE CAPABLE OF OBTAINING MOLECULAR LEVEL SARCOMERE STRUCTURAL DATA FROM LIVE CARDIAC MUSCLE. SARCOMERE FUNCTION WILL BE ASSESSED BOTH AT ARGONNE AND AT NEARBY LOYOLA UNIVERSITY CHICAGO ON CUSTOM BIOPHYSICAL SETUPS. LASTLY, SARCOMERE STRUCTURE AND FUNCTION ARE REGULATED BY PROTEIN POST-TRANSLATIONAL MODIFICATIONS (PTMS) AND ISOFORM SWITCHING, WHICH WILL BE ASSESSED USING OUR TOP-OF-THE-LINE MASS SPECTROMETRY INSTRUMENTATION. WE WILL INVESTIGATE THE STRUCTURAL BASIS OF MYOFILAMENT FUNCTIONAL DYSREGULATION IN HEALTHY, HYPERTROPHIC (HCM: MYH7R403Q, MYBPC330X), DILATED (DCM: TTN16648X, RBM20R636S) CARDIOMYOPATHY TRANSGENIC PIGS ACROSS THE FOLLOWING THREE AIMS. THESE STUDIES WILL REVEAL THE UNDERLYING STRUCTURAL BASIS FOR CARDIOMYOPATHIES RESULTING FROM SARCOMERE PROTEIN VARIANTS, REVEALING TRANSLATIONAL MECHANISTIC UNDERSTANDING NECESSARY TO TREAT THESE DISEASES. IN AIM 1 WE WILL DETERMINE THE IMPACT OF HCM AND DCM MUTATIONS ON NORMAL SARCOMERE STRUCTURE. WE WILL COLLECT X-RAY DIFFRACTION PATTERNS AND FUNCTIONAL DATA FROM LIVE PORCINE CARDIAC MUSCLE TO INVESTIGATE THE STRUCTURAL BASIS OF PROTEIN VARIANTS LEADING TO HCM AND DCM. IN AIM 2 WE WILL DETERMINE THE IMPACT OF PHYSIOLOGICAL INOTROPIC INTERVENTIONS IN HCM AND DCM. A MAJOR PATHOLOGICAL MECHANISM OF THESE DISEASE-CAUSING VARIANTS IS THAT THEY MODIFY THE SARCOMERE'S ABILITY TO RESPOND APPROPRIATELY TO NORMAL PHYSIOLOGICAL CONDITIONS. HERE WE WILL ASSESS THE RESPONSE TO CONDITIONS WHICH TYPICALLY ELICIT AN IONOTROPIC RESPONSE. IN AIM 3 WE WILL DETERMINE HOW HCM AND DCM MUTATIONS AFFECT SARCOMERE FUNCTION REGULATION BY POST-TRANSLATIONAL MODIFICATIONS.

Posted 6/11/24, 12:00 AM